FibroBiologics (FBLG) Enterprise Value (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Enterprise Value of -$3.5 million for Q2 2026, up 60.26% year-over-year from -$2.2 million in Q2 2025, and down 134.33% on a QoQ basis from -$1.5 million in Q1 2026.
FibroBiologics (FBLG) Enterprise Value (2022 - 2026) Analysis & Trends
FibroBiologics has reported Enterprise Value for 5 years, with the latest figure at -$3.5 million in Q2 2026.
- Enterprise Value for Q2 2026 came in at -$3.5 million, up 60.26% year-over-year; the trailing twelve-month figure through Jun 2026 was -$3.5 million (up 60.26% YoY), and the FY2025 annual result was -$4.9 million, up 65.0% from the prior year.
- Enterprise Value declined to -$3.5 million in Q2 2026, from -$1.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.5 million in Q1 2026 and troughed at -$14.0 million in Q4 2024.
- A 5-year average of -$6.6 million and a median of -$6.9 million in 2024 frame the typical range for Enterprise Value.
- The widest annual swing landed in 2023, when Enterprise Value plunged 304.37%; it then surged 82.69% in 2026.
- A 5-year view of Enterprise Value shows it stood at -$2.3 million in 2022, then plunged by 304.37% to -$9.2 million in 2023, then sank by 52.79% to -$14.0 million in 2024, then soared by 65.0% to -$4.9 million in 2025, then grew by 28.27% to -$3.5 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$3.5 million in Q2 2026, -$1.5 million in Q1 2026, and -$4.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | -3.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.52 Mn |
| Mar 31, 2026 | -1.48 Mn |
| Dec 31, 2025 | -4.89 Mn |
| Sep 30, 2025 | -4.90 Mn |
| Jun 30, 2025 | -8.85 Mn |
| Mar 31, 2025 | -7.85 Mn |
| Dec 31, 2024 | -13.99 Mn |
| Sep 30, 2024 | -6.49 Mn |
| Jun 30, 2024 | -5.51 Mn |
| Mar 31, 2024 | -6.04 Mn |
| Dec 31, 2022 | -2.27 Mn |